Dr. Slapak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
The Wishard Hospital Hematology Clinic
1050 Wishard Blvd
Indianapolis, IN 46202Phone+1 317-630-7175Fax+1 317-630-6310
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1991
University of ChicagoResidency, Internal Medicine, 1984 - 1987
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1984
Certifications & Licensure
IN State Medical License 1996 - 2025
IL State Medical License 1986 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 55 citationsA first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.Saroj Vadhan-Raj, Rafat Abonour, Jonathan W. Goldman, David Smith, Christopher A. Slapak
Journal of Hematology & Oncology. 2017-03-21 - 410 citationsClinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathwayStephan Herbertz, J. Scott Sawyer, Anja Stauber, Ivelina Gueorguieva, Kyla Driscoll
Drug Design, Development and Therapy. 2015-08-10 - 28 citationsPhase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular LymphomaKristen N. Ganjoo, Sven de Vos, Brad Pohlman, Ian W. Flinn, Andres Forero-Torres
Leukemia & Lymphoma. 2015-01-01
Press Mentions
PureTech Founded Entity Vor Announces FDA Clearance of IND Application for VOR33January 14th, 2021- Vor Announces FDA Clearance of IND Application for VOR33January 14th, 2021
- Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer InstituteNovember 11th, 2020
- Join now to see all
Grant Support
- Anthracycline Efflux In Multiresistant Leukemia CellsNational Cancer Institute1991–1995
- Anthracycline Efflux In Multiresistant Leukemia CellsNational Cancer Institute1991
- Early Doxorubicin Resistant Mammalian Leukemia CellsNational Cancer Institute1989–1990
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
